Horizon Therapeutics Public Limited Company ( HZNP) Stock. Should you Buy or Sell? $ 66.09
4.06 (5.79 %)
Horizon Therapeutics Public Limited Company Analysis
Updated on 10-09-2022| Symbol | HZNP |
| Price | $66.09 |
| Beta | 1.108 |
| Volume Avg. | $2.63 M |
| Market Cap | $15.23 B |
| 52 Week Range | $57.84 - $120.54 |
Horizon Therapeutics Public Limited Company opened the day at $66.09 which is +'5.79 % on yesterday's close. Horizon Therapeutics Public Limited Company has a 52 week high of $120.54 and 52 week low of $57.84, which is a difference of $62.7. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $15.23 B and total net profit is $3226410000 which means the company is trading at 4.72 times profit to market capitalization. Theoretically, if you were to buy Horizon Therapeutics Public Limited Company for $15.23 B, it would take 15 years to get your money back. Horizon Therapeutics Public Limited Company are in the Drug Manufacturers—General space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
Financials
Horizon Therapeutics Public Limited Company Stock Forecast - Is Horizon Therapeutics Public Limited Company a Buy or Sell?
| DCF Score | Strong Buy | |
| ROE Score | Neutral | |
| ROA Score | Neutral | |
| DE Score | Buy | |
| PE Score | Strong Buy | |
| PB Score | Strong Buy | |
| Overall Recommendation | Strong Buy |
Growth and Value
| PE Ratio | 19.847 |
| Dividend Yiel | 0.000 |
| Net Profit Margin | 0.201 |
Valuing Horizon Therapeutics Public Limited Company
| Price Book Value Ratio | 3.074 | Price To Book Ratio | 3.074 |
| Price To Sales Ratio | 3.987 | Price Earnings Ratio | 19.873 |
How liquid is Horizon Therapeutics Public Limited Company
| Current Ratio | 4.049 |
| Quick Ratio | 3.244 |
Debt
| Debt Ratio | 0.441 | Debt Equity Ratio | 0.790 |
| Long Term Debt To Capitalization | 0.340 | Total Debt To Capitalization | 0.342 |
Latest news about Horizon Therapeutics Public Limited Company
The top five biotech stocks today have several commonalities: strong ratings. Some also show promising charts and are Tech Leaders.
Shares of Horizon Therapeutics are down 50% from last year's highs, a consequence of a prolonged biotech market and recent setbacks. The Tepezza growth scare is the main reason the stock is trading at current levels, but Tepezza remains well-positioned for long-term growth with multiple catalysts ahead.
Viridian Therapeutics hopes to follow Horizon Therapeutics with a best thyroid eye disease drug, and the IPO stock is on a run. The post Why Viridian's CEO Isn't Sweating His Company's Second-Place Position appeared first on Investor's Business Daily.
Horizon's (HZNP) portfolio of marketed drugs, including Tepezza and Krystexxa, aid growth. The company is also working on the label expansion of its drugs.
Shares have lost 40% of their value year to date. Tepezza sales should reaccelerate into the back half of 2022 and 2023 as the drug makes inroads into chronic TED market.
About Horizon Therapeutics Public Limited Company
Description :
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC.; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; and Arrowhead Pharmaceuticals, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; Lake Forest, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.
